trial
as of 2026-07-01Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
NCTId NCT01400113
at a glance
Phase 4 · Completed
Enrollment 120 (actual)
Sponsored by Unity Health Toronto
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-04
Primary completion
2012-12
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Unity Health TorontoLead Sponsor
Schering-PloughCollaborator
Investigators
3
Michael J Pratts, MDPrincipal Investigator
Laura Leso, MDPrincipal Investigator
David Frey, MDPrincipal Investigator
Sites
1 total
Syracuse, United States
Facts & assertions
4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
investigator